Zymeworks BC Inc ZYME

NAS: ZYME | ISIN: US98985Y1082   20/05/2025
12,43 USD (+5,16%)
(+5,16%)   20/05/2025

21 mei 2025 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

19 mei 2025 · Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference · Persbericht

25 april 2025 · Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting · Persbericht

21 april 2025 · Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development · Persbericht

26 maart 2025 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

25 maart 2025 · Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting · Persbericht

26 februari 2025 · Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration · Persbericht

25 februari 2025 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

13 februari 2025 · Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 · Persbericht

30 januari 2025 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

8 januari 2025 · Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 · Persbericht

12 december 2024 · Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases · Persbericht

21 november 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

21 november 2024 · FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) · Persbericht

5 november 2024 · Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors · Persbericht

29 oktober 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

25 oktober 2024 · Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference · Persbericht

21 oktober 2024 · Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers · Persbericht

18 september 2024 · Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference · Persbericht

22 augustus 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

Mijn selecties